Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

March 24, 2023

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

News Daily News

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

March 31, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

Pneumonia in HF Patients Is Common, Lethal, and Preventable

News Daily News

Pneumonia in HF Patients Is Common, Lethal, and Preventable

April 19, 2021

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

January 11, 2021

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

September 18, 2019

News Daily News

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

July 13, 2015

News Daily News

FDA批准了一种具有生存优势的心力衰竭药物

July 13, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

July 13, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advances in Heart Failure Therapy: PARADIGM-HF

Presentation CATCH-UP 2015

Advances in Heart Failure Therapy: PARADIGM-HF

Presenter: Mat Maurer

April 25, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.